Bepirovirsen Delivers a Functional Cure in About One in Five Chronic Hepatitis B Patients in Phase 3 Trials
GSK's antisense drug bepirovirsen cleared chronic HBV in 20% and 19% of patients across two Phase 3 trials, versus none on placebo, the NEJM reports.